Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 65, Issue , 2016, Pages 34-48

  Iasevoli, Felice ^a   Giordano, Sara ^a   Balletta, Raffaele ^a   Latte, Gianmarco ^a   Formato, Maria Vittoria ^a   Prinzivalli, Emiliano ^a   De Berardis, Domenico ^b,d   Tomasetti, Carmine ^a,c   de Bartolomeis, Andrea ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b G Mazzini Hospital   (Italy)

^c Department of Mental Health ASL Teramo   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cognitive; PANSS; Psychosis; Psychosocial; Quality of life

Indexed keywords

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL TASK; OUTCOME ASSESSMENT; PREDICTION; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; TASK PERFORMANCE; YOUNG ADULT; ACHIEVEMENT; ANXIETY DISORDERS; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG RESISTANCE; EMPLOYMENT; MARRIAGE; PATHOPHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

NEUROLEPTIC AGENT;

ACHIEVEMENT; ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; COGNITION; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; DRUG RESISTANCE; EMPLOYMENT; FEMALE; HUMANS; MALE; MARITAL STATUS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84941299519     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.08.010     Document Type: Article

References (75)

1. Altamura A.C. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. Schizophr. Res. 1993, 8:187-198.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
3. Anselmetti S., Poletti S., Ermoli E., Bechi M., Cappa S., Venneri A., Smeraldi E., Cavallaro R. The brief assessment of cognition in schizophrenia. Normative data for the Italian population. Neurol. Sci. 2008, 29:85-92.
4. Awad A.G., Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004, 18:877-893.
5. Beck K., McCutcheon R., Bloomfield M.A., Gaughran F., Reis Marques T., MacCabe J., Selvaraj S., Taylor D., Howes O.D. The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatr. Scand. 2014, 130:427-438.
6. Bowie C.R., Twamley E.W., Anderson H., Halpern B., Patterson T.L., Harvey P.D. Self-assessment of functional status in schizophrenia. J. Psychiatr. Res. 2007, 41:1012-1018.
7. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., Harvey P.D. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 2008, 63:505-511.
8. Bowie C.R., McGurk S.R., Mausbach B., Patterson T.L., Harvey P.D. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am. J. Psychiatry 2012, 169:710-718.
9. Burton C.Z., Vella L., Harvey P.D., Patterson T.L., Heaton R.K., Twamley E.W. Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. Schizophr. Res. 2013, 146:244-248.
10. Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P., Baldessarini R.J. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am. J. Psychiatry 2004, 161:700-706.
11. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 2001, 50:898-911.
12. Couture S.M., Granholm E.L., Fish S.C. A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophr. Res. 2011, 125:152-160.
13. de Bartolomeis A., Balletta R., Giordano S., Buonaguro E.F., Latte G., Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Res. 2013, 210:387-395.
14. De Silva M.J., Cooper S., Li H.L., Lund C., Patel V. Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. Br. J. Psychiatry 2013, 202:253-260.
15. Demjaha A., Murray R.M., McGuire P.K., Kapur S., Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am. J. Psychiatry 2012, 169:1203-1210.
16. Demjaha A., Egerton A., Murray R.M., Kapur S., Howes O.D., Stone J.M., McGuire P.K. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol. Psychiatry 2014, 75:e11-e13.
17. Dickinson D., Bellack A.S., Gold J.M. Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr. Bull. 2007, 33:1213-1220.
18. Dixon L.B., Dickerson F., Bellack A.S., Bennett M., Dickinson D., Goldberg R.W., Lehman A., Tenhula W.N., Calmes C., Pasillas R.M., Peer J., Kreyenbuhl J. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:48-70. Schizophrenia Patient Outcomes Research T.
19. Fallon P., Dursun S.M. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J. Psychopharmacol. 2011, 25:755-762.
20. Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., Marcus R., McQuade R.D., Iwamoto T., Carson W.H. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J. Psychiatry 2008, 165:1432-1441.
21. Frank J., Lang M., Witt S.H., Strohmaier J., Rujescu D., Cichon S., Degenhardt F., Nothen M.M., Collier D.A., Ripke S., Naber D., Rietschel M. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol. Psychiatry 2015, 20:150-151.
22. Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P., Rucci P., Gibertoni D., Aguglia E., Amore M., Bellomo A., Biondi M., Brugnoli R., Dell'Osso L., De Ronchi D., Di Emidio G., Di Giannantonio M., Fagiolini A., Marchesi C., Monteleone P., Oldani L., Pinna F., Roncone R., Sacchetti E., Santonastaso P., Siracusano A., Vita A., Zeppegno P., Maj M. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry 2014, 13:275-287. Italian Network For Research on P.
23. Gilbert E., Merette C., Jomphe V., Emond C., Rouleau N., Bouchard R.H., Roy M.A., Paccalet T., Maziade M. Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264:333-343.
24. Harvey P.D. Direct measurement of disability. Psychiatry (Edgmont) 2009, 6:43-46.
25. Harvey P.D., Velligan D.I. International assessment of functional skills in people with schizophrenia. Innov. Clin. Neurosci. 2011, 8:15-18.
26. Harvey P.D., Velligan D.I., Bellack A.S. Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr. Bull. 2007, 33:1138-1148.
27. Harvey P.D., Helldin L., Bowie C.R., Heaton R.K., Olsson A.K., Hjarthag F., Norlander T., Patterson T.L. Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. Am. J. Psychiatry 2009, 166:821-827.
28. Harvey P.D., Raykov T., Twamley E.W., Vella L., Heaton R.K., Patterson T.L. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am. J. Psychiatry 2011, 168:1195-1201.
29. Harvey P.D., Sabbag S., Prestia D., Durand D., Twamley E.W., Patterson T.L. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J. Psychiatr. Res. 2012, 46:1546-1552.
30. Howes O.D., Vergunst F., Gee S., McGuire P., Kapur S., Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br. J. Psychiatry 2012, 201:481-485.
31. Iasevoli F., Balletta R., Gilardi V., Giordano S., de Bartolomeis A. Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatr. Dis. Treat. 2013, 9:1113-1120.
32. Iasevoli F., Buonaguro E.F., Marconi M., Di Giovambattista E., Rapagnani M.P., De Berardis D., Martinotti G., Mazza M., Balletta R., Serroni N., Di Giannantonio M., de Bartolomeis A., Valchera A. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. ISRN Pharmacol. 2014, 2014:762127.
33. Kane J.M. Treatment-resistant schizophrenic patients. J. Clin. Psychiatry 1996, 57(Suppl. 9):35-40.
34. Kaneda Y., Jayathilak K., Meltzer H. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry Res. 2010, 178:57-62.
35. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
36. Kimura H., Kanahara N., Komatsu N., Ishige M., Muneoka K., Yoshimura M., Yamanaka H., Suzuki T., Komatsu H., Sasaki T., Hashimoto T., Hasegawa T., Shiina A., Ishikawa M., Sekine Y., Shiraishi T., Watanabe H., Shimizu E., Hashimoto K., Iyo M. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr. Res. 2014, 155:52-58.
37. Kolakowska T., Williams A.O., Ardern M., Reveley M.A., Jambor K., Gelder M.G., Mandelbrote B.M. Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br. J. Psychiatry 1985, 146:229-239.
38. Kozma C.M., Dirani R.G., Canuso C.M., Mao L. Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension. Ann. Gen. Psychiatry 2010, 9:24.
39. Lambert M., Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004, 18(Suppl. 2):5-17. (discussion 41-3).
40. Lee J., Fervaha G., Takeuchi H., Powell V., Remington G. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia. J. Clin. Psychopharmacol. 2015, 35:237-241.
41. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J., American Psychiatric A. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161:1-56. Steering Committee on Practice G.
42. Leifker F.R., Patterson T.L., Heaton R.K., Harvey P.D. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 2011, 37:334-343.
43. Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin. Neuropharmacol. 2003, 26:58-61.
44. Leucht S., Kane J.M., Etschel E., Kissling W., Hamann J., Engel R.R. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006, 31:2318-2325.
45. Leung W.W., Bowie C.R., Harvey P.D. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study. J. Int. Neuropsychol. Soc. 2008, 14:479-488.
46. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229.
47. Lindenmayer J.P. Treatment refractory schizophrenia. Psychiatry Q. 2000, 71:373-384.
48. Mace S., Taylor D. Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme. Ther. Adv. Psychopharmacol. 2015, 5:4-12.
49. Meltzer H.Y. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990, 16:563-565.
50. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101:323-329.
51. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
52. Obermeier M., Schennach-Wolff R., Meyer S., Moller H.J., Riedel M., Krause D., Seemuller F. Is the PANSS used correctly? A systematic review. BMC Psychiatry 2011, 11:113.
53. Olfson M., Ascher-Svanum H., Faries D.E., Marcus S.C. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatr. Serv. 2011, 62:1138-1145.
54. Paton C., Barnes T.R., Cavanagh M.R., Taylor D., Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br. J. Psychiatry 2008, 192:435-439. team P-Up.
55. Pierre J.M., Wirshing D.A., Wirshing W.C., Rivard J.M., Marks R., Mendenhall J., Sheppard K., Saunders D.G. High-dose quetiapine in treatment refractory schizophrenia. Schizophr. Res. 2005, 73:373-375.
56. Quarantelli M., Palladino O., Prinster A., Schiavone V., Carotenuto B., Brunetti A., Marsili A., Casiello M., Muscettola G., Salvatore M., de Bartolomeis A. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia. Biomed. Res. Int. 2014, 2014:325052.
57. Rocca P., Montemagni C., Zappia S., Pitera R., Sigaudo M., Bogetto F. Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting. Psychiatry Res. 2014, 218:284-289.
58. Rosenheck R., Leslie D., Keefe R., McEvoy J., Swartz M., Perkins D., Stroup S., Hsiao J.K., Lieberman J. Barriers to employment for people with schizophrenia. Am. J. Psychiatry 2006, 163:411-417. Group CSI.
59. Rossi A., Arduini L., De Cataldo S., Stratta P. Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI). Epidemiol. Psichiatr. Soc. 2001, 10:107-114.
60. Rossi A., Rucci P., Mauri M., Maina G., Pieraccini F., Pallanti S., Endicott J. Validity and reliability of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Qual. Life Res. 2005, 14:2323-2328.
61. Rossi A., Bagala A., Del Curatolo V., Scapati F., Bernareggi M.M., Giustra M.G. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum. Psychopharmacol. 2009, 24:574-583. I. Risperidone Long-Acting Trial.
62. Sabbag S., Twamley E.M., Vella L., Heaton R.K., Patterson T.L., Harvey P.D. Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr. Res. 2011, 131:250-255.
63. Schottle D., Schimmelmann B.G., Karow A., Ruppelt F., Sauerbier A.L., Bussopulos A., Frieling M., Golks D., Kerstan A., Nika E., Schodlbauer M., Daubmann A., Wegscheider K., Lange M., Ohm G., Lange B., Meigel-Schleiff C., Naber D., Wiedemann K., Bock T., Lambert M. Effectiveness of integrated care including therapeutic assertive community treatment in severe schizophrenia spectrum and bipolar I disorders: the 24-month follow-up ACCESS II study. J. Clin. Psychiatry 2014, 75:1371-1379.
64. Sheitman B.B., Lieberman J.A. The natural history and pathophysiology of treatment resistant schizophrenia. J. Psychiatr. Res. 1998, 32:143-150.
65. Sim F., Sweetman I., Kapur S., Patel M.X. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J. Psychopharmacol. 2015, 29:212-223.
66. Stip E., Lussier I., Ngan E., Mendrek A., Liddle P. Discriminant cognitive factors in responder and non-responder patients with schizophrenia. Eur. Psychiatry 1999, 14:442-450.
67. Strassnig M.T., Raykov T., O'Gorman C., Bowie C.R., Sabbag S., Durand D., Patterson T.L., Pinkham A., Penn D.L., Harvey P.D. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr. Res. 2015, 165(1):76-82.
68. Suzuki T., Kanahara N., Yamanaka H., Takase M., Kimura H., Watanabe H., Iyo M. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015, 227(2-3):278-282.
69. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A., Investigators C. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436.
70. Szeszko P.R., Narr K.L., Phillips O.R., McCormack J., Sevy S., Gunduz-Bruce H., Kane J.M., Bilder R.M., Robinson D.G. Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr. Bull. 2012, 38:569-578.
71. Tadokoro S., Okamura N., Sekine Y., Kanahara N., Hashimoto K., Iyo M. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr. Bull. 2012, 38:1012-1020.
72. Takase M., Kanahara N., Oda Y., Kimura H., Watanabe H., Iyo M. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J. Psychopharmacol. 2015, 29:383-389.
73. Twamley E.W., Doshi R.R., Nayak G.V., Palmer B.W., Golshan S., Heaton R.K., Patterson T.L., Jeste D.V. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am. J. Psychiatry 2002, 159:2013-2020.
74. Twamley E.W., Woods S.P., Zurhellen C.H., Vertinski M., Narvaez J.M., Mausbach B.T., Patterson T.L., Jeste D.V. Neuropsychological substrates and everyday functioning implications of prospective memory impairment in schizophrenia. Schizophr. Res. 2008, 106:42-49.
75. Wiersma D., Wanderling J., Dragomirecka E., Ganev K., Harrison G., An Der Heiden W., Nienhuis F.J., Walsh D. Social disability in schizophrenia: its development and prediction over 15years in incidence cohorts in six European centres. Psychol. Med. 2000, 30:1155-1167.